Notice of Results

RNS Number : 8030Y

Shield Therapeutics PLC

14 September 2020

 

Shield Therapeutics plc

("Shield" or the "Group" or the "Company")

Notice of Results

Analyst and Investor Briefings

London, UK, 14 September 2020:  Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol),   will announce its interim results for the six months ended 30 June 2020 on Wednesday 16 September 2020.

Analyst briefing

A briefing open to analysts will take place remotely via video conference call on Wednesday 16 September 2020 at 11.00am. If you would like the details of this call please contact Walbrook PR on [e-mail].

Investor briefing

Shield Therapeutics will be hosting a live online presentation open to all investors on Wednesday 16 September at 4.30pm. The Company is committed to providing an opportunity for all existing and potential investors to hear directly from management on the recent developments and additionally providing an update on the business.

The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via the following link:

https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor

For those investors who have already registered and added to meet the Company, they will automatically be invited.

Questions can be submitted pre-event   via your Investor Meet Company dashboard  or in real time during the presentation, via the "Ask a Question" function.  Whilst the Company may not be in a position to answer every question it receives, it will aim to address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Tim Watts, CEO	[phone]
Karen Chandler Smith, Investor Relations
Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden	[phone]
Joint Broker finnCap Ltd  Geoff Nash/Matt Radley/Alice Lane	[phone]
Financial PR & IR Advisor
Walbrook PR	[phone] or  [e-mail]
Paul McManus/Lianne Cawthorne	[phone] / [phone]

About Shield Therapeutics plc

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market.  Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

 

END

 

 

NORBUGDCSDBDGGB